UPMC sues over hospital’s pensions[/naviga:h3] ALTOONA — The University of Pittsburgh Medical Center has filed a lawsuit against a Cleveland firm, alleging that an actuarial employee vastly understated the pension liability of the hospital that’s now UPMC Altoona. UPMC filed the lawsuit against CBIZ Inc. in federal court last week. UPMC says in the lawsuit that it wouldn’t have acquired Altoona Regional Health System in 2013 had it known the hospital’s full liability. The lawsuit says the liability was $123 million more than what was stated in pension documents. The lawsuit names CBIZ and its now-retired, Maryland-based actuary, Jon Ketzner, as defendants. UPMC is seeking $142 million in damages, plus punitive damages. CBIZ says it plans to vigorously contest the allegations. Ketzner referred a request for comment to CBIZ. [naviga:h3]UPS testing drones for package delivery[/naviga:h3] MARBLEHEAD, Mass. — One of the world’s largest package delivery companies is stepping up efforts to integrate drones into its system. UPS has partnered with robot-maker CyPhy Works to test the use of drones to make commercial deliveries to remote or difficult-to-access locations. The companies began testing the drones on Thursday, when they launched one from the seaside town of Marblehead. The drone flew on a programmed route for 3 miles over the Atlantic Ocean to deliver an inhaler at Children’s Island. The successful landing was greeted by jubilant shouts from CyPhy Works and UPS employees on the island to witness the test. “I thought it was fantastic,” said John Dodero, UPS vice president for industrial engineering. CyPhy Works founder Helen Greiner, who previously co-founded robot-maker iRobot, said the drone tests with UPS allow her company to gather engineering and cost information and then work with UPS to look at where drones can add the most value to UPS’ extensive network. Still, the robot-maker doesn’t see drones replacing delivery trucks, bikes, buggies or gondolas anytime soon. [naviga:h3]Lower-cost version of Humira approved[/naviga:h3] WASHINGTON — Federal regulators on Friday approved the first alternative version of the second-best selling drug in the world, Humira, the blockbuster injection used to treat rheumatoid arthritis and other inflammatory diseases. The Food and Drug Administration cleared a near-copy of the drug, dubbed Amjevita, developed by Amgen Inc. Regulators approved the drug for more than a half-dozen conditions listed on the original drug’s label, including severe psoriasis and Crohn’s diseases. Humira posted sales of nearly $15 billion in 2015 and was for many years the top-selling prescription drug in the world, according to data from IMS Health. It’s the fourth time that the FDA has formally approved a so-called biosimilar, the industry term for a lower-cost version of a biotech drug. Biosimilar drugs, long available in Europe, are thought to have the potential to generate billions in savings for the U.S. health system.